<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benboubker, L.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Dispenzieri, A.</style></author><author><style face="normal" font="default" size="100%">Catalano, J.</style></author><author><style face="normal" font="default" size="100%">Belch, A.R.</style></author><author><style face="normal" font="default" size="100%">Cavo, M.</style></author><author><style face="normal" font="default" size="100%">Pinto, A.</style></author><author><style face="normal" font="default" size="100%">Weisel, K.</style></author><author><style face="normal" font="default" size="100%">Ludwig, H.</style></author><author><style face="normal" font="default" size="100%">Bahlis, N.</style></author><author><style face="normal" font="default" size="100%">Banos, A.</style></author><author><style face="normal" font="default" size="100%">Tiab, M.</style></author><author><style face="normal" font="default" size="100%">Delforge, M.</style></author><author><style face="normal" font="default" size="100%">Cavenagh, J.</style></author><author><style face="normal" font="default" size="100%">Geraldes, C.</style></author><author><style face="normal" font="default" size="100%">Lee, J.-J.</style></author><author><style face="normal" font="default" size="100%">Chen, C.</style></author><author><style face="normal" font="default" size="100%">Oriol, A.</style></author><author><style face="normal" font="default" size="100%">De La Rubia, J.</style></author><author><style face="normal" font="default" size="100%">Qiu, L.</style></author><author><style face="normal" font="default" size="100%">White, D.J.</style></author><author><style face="normal" font="default" size="100%">Binder, D.</style></author><author><style face="normal" font="default" size="100%">Anderson, K.</style></author><author><style face="normal" font="default" size="100%">Fermand, J.-P.</style></author><author><style face="normal" font="default" size="100%">Moreau, P.</style></author><author><style face="normal" font="default" size="100%">Attal, M.</style></author><author><style face="normal" font="default" size="100%">Knight, R.</style></author><author><style face="normal" font="default" size="100%">Chen, G.</style></author><author><style face="normal" font="default" size="100%">Van Oostendorp, J.</style></author><author><style face="normal" font="default" size="100%">Jacques, C.</style></author><author><style face="normal" font="default" size="100%">Ervin-Haynes, A.</style></author><author><style face="normal" font="default" size="100%">Avet-Loiseau, H.</style></author><author><style face="normal" font="default" size="100%">Hulin, C.</style></author><author><style face="normal" font="default" size="100%">Facon, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84907012637&amp;doi=10.1056%2fNEJMoa1402551&amp;partnerID=40&amp;md5=bc2ec4244550fe131c44a2bcab95a067</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">371</style></volume><pages><style face="normal" font="default" size="100%">906 - 917</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P&lt;0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. Conclusions: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. Copyright © 2014 Massachusetts Medical Society.</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><notes><style face="normal" font="default" size="100%">Cited By :166Export Date: 21 February 2017</style></notes></record></records></xml>